{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Ranibizumab+Placebo", "query": { "intervention": "Ranibizumab Placebo" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 13, "total_pages": 2, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Ranibizumab+Placebo&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-27T00:24:12.857Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00436553", "title": "Efficacy/Safety of Verteporfin Photodynamic Therapy and Ranibizumab Compared With Ranibizumab in Patients With Subfoveal Choroidal Neovascularization", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Macular Degeneration", "Choroidal Neovascularization" ], "interventions": [ { "name": "Verteporfin Photodynamic Therapy", "type": "DRUG" }, { "name": "Ranibizumab", "type": "DRUG" }, { "name": "Verteporfin Placebo", "type": "DRUG" }, { "name": "Ranibizumab Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "ALL", "summary": "50 Years and older" }, "enrollment_count": 321, "start_date": "2007-02", "completion_date": "2009-10", "has_results": true, "last_update_posted_date": "2011-04-19", "last_synced_at": "2026-09-27T00:24:12.857Z", "location_count": 36, "location_summary": "Tucson, Arizona • Beverly Hills, California • Oakland, California + 33 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Oakland", "state": "California" }, { "city": "Pasadena", "state": "California" }, { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00436553" }, { "nct_id": "NCT01134055", "title": "Dose Ranging Study of Pazopanib to Treat Neovascular Age-Related Macular Degeneration", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Macular Degeneration" ], "interventions": [ { "name": "pazopanib eye drops", "type": "DRUG" }, { "name": "placebo", "type": "DRUG" }, { "name": "ranibizumab intravitreal injection", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "ALL", "summary": "50 Years and older" }, "enrollment_count": 510, "start_date": "2010-06-01", "completion_date": "2012-10-01", "has_results": true, "last_update_posted_date": "2018-01-08", "last_synced_at": "2026-09-27T00:24:12.857Z", "location_count": 37, "location_summary": "Peoria, Arizona • Phoenix, Arizona • Tucson, Arizona + 31 more", "locations": [ { "city": "Peoria", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT01134055" }, { "nct_id": "NCT01414153", "title": "Efficacy and Safety Study of iSONEP With & Without Lucentis/Avastin/Eylea to Treat Wet AMD", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Exudative Age-related Macular Degeneration" ], "interventions": [ { "name": "4.0 mg iSONEP", "type": "DRUG" }, { "name": "0.5 mg iSONEP", "type": "DRUG" }, { "name": "0.5 mg Lucentis or 1.25 mg Avastin or 2 mg Eylea", "type": "DRUG" }, { "name": "sham injection", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Lpath, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "ALL", "summary": "50 Years and older" }, "enrollment_count": 158, "start_date": "2012-08", "completion_date": "2015-06", "has_results": true, "last_update_posted_date": "2016-10-17", "last_synced_at": "2026-09-27T00:24:12.857Z", "location_count": 44, "location_summary": "Peoria, Arizona • Phoenix, Arizona • Tucson, Arizona + 38 more", "locations": [ { "city": "Peoria", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Beverly Hills", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01414153" }, { "nct_id": "NCT02511613", "title": "Effect of Squalamine Lactate Ophthalmic Solution, 0.2% in Subjects With Neovascular Age-Related Macular Degeneration", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Age-Related Macular Degeneration" ], "interventions": [ { "name": "Squalamine Lactate Ophthalmic Solution, 0.2%", "type": "DRUG" }, { "name": "Placebo Ophthalmic Solution", "type": "DRUG" }, { "name": "ranibizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ohr Pharmaceutical Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "ALL", "summary": "50 Years and older" }, "enrollment_count": 0, "start_date": "2015-07", "completion_date": "2016-04", "has_results": false, "last_update_posted_date": "2017-04-27", "last_synced_at": "2026-09-27T00:24:12.857Z", "location_count": 4, "location_summary": "Beverly Hills, California • Hagerstown, Maryland • New York, New York + 1 more", "locations": [ { "city": "Beverly Hills", "state": "California" }, { "city": "Hagerstown", "state": "Maryland" }, { "city": "New York", "state": "New York" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02511613" }, { "nct_id": "NCT02222207", "title": "Regorafenib Eye Drops: Investigation of Efficacy and Safety in Neovascular Age Related Macular Degeneration", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Macular Degeneration" ], "interventions": [ { "name": "Regorafenib, ophthalmic oily suspension (BAY73-4506)", "type": "DRUG" }, { "name": "Sham IVT", "type": "PROCEDURE" }, { "name": "Ranibizumab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "ALL", "summary": "50 Years and older" }, "enrollment_count": 52, "start_date": "2014-10", "completion_date": "2015-06", "has_results": true, "last_update_posted_date": "2016-09-08", "last_synced_at": "2026-09-27T00:24:12.857Z", "location_count": 37, "location_summary": "Tucson, Arizona • Arcadia, California • Beverly Hills, California + 34 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Arcadia", "state": "California" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Campbell", "state": "California" }, { "city": "Costa Mesa", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02222207" }, { "nct_id": "NCT00444600", "title": "Laser-Ranibizumab-Triamcinolone for Diabetic Macular Edema", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Diabetic Retinopathy", "Diabetic Macular Edema" ], "interventions": [ { "name": "Triamcinolone Acetonide + laser", "type": "DRUG" }, { "name": "Ranibizumab + laser", "type": "DRUG" }, { "name": "Sham injection + laser", "type": "DRUG" }, { "name": "Ranibizumab + deferred laser", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Jaeb Center for Health Research", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 691, "start_date": "2007-03", "completion_date": "2014-02", "has_results": true, "last_update_posted_date": "2019-10-07", "last_synced_at": "2026-09-27T00:24:12.857Z", "location_count": 50, "location_summary": "Artesia, California • Beverly Hills, California • Irvine, California + 42 more", "locations": [ { "city": "Artesia", "state": "California" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "Loma Linda", "state": "California" }, { "city": "Palm Springs", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00444600" }, { "nct_id": "NCT02727881", "title": "Efficacy and Safety Study of Squalamine Ophthalmic Solution in Subjects With Neovascular AMD", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Age-related Macular Degeneration" ], "interventions": [ { "name": "Squalamine lactate ophthalmic solution, 0.2%", "type": "DRUG" }, { "name": "Placebo Ophthalmic solution", "type": "DRUG" }, { "name": "ranibizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ohr Pharmaceutical Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": "110 Years", "sex": "ALL", "summary": "50 Years to 110 Years" }, "enrollment_count": 230, "start_date": "2016-04-12", "completion_date": "2017-12", "has_results": false, "last_update_posted_date": "2017-04-27", "last_synced_at": "2026-09-27T00:24:12.857Z", "location_count": 118, "location_summary": "Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 106 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT02727881" }, { "nct_id": "NCT00766337", "title": "Phase 2 Study of an Ocular Sirolimus (Rapamycin) Formulation in Combination With Lucentis® in Patients With Age-Related Macular Degeneration", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Age-Related Macular Degeneration", "Choroidal Neovascularization" ], "interventions": [ { "name": "Sirolimus in combination with ranibizumab", "type": "DRUG" }, { "name": "Placebo in combination with ranibizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Santen Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "ALL", "summary": "50 Years and older" }, "enrollment_count": 62, "start_date": "2008-12", "completion_date": "2010-03", "has_results": false, "last_update_posted_date": "2013-01-10", "last_synced_at": "2026-09-27T00:24:12.857Z", "location_count": 1, "location_summary": "Phoenix, Arizona", "locations": [ { "city": "Phoenix", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT00766337" }, { "nct_id": "NCT02355028", "title": "LHA510 Proof-of-Concept Study as a Maintenance Therapy for Patients With Wet Age-Related Macular Degeneration", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Exudative Age-Related Macular Degeneration" ], "interventions": [ { "name": "LHA510 ophthalmic suspension", "type": "DRUG" }, { "name": "LHA510 vehicle", "type": "DRUG" }, { "name": "Ranibizumab ophthalmic solution", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Alcon, a Novartis Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": "90 Years", "sex": "ALL", "summary": "50 Years to 90 Years" }, "enrollment_count": 136, "start_date": "2015-03-03", "completion_date": "2016-10-18", "has_results": true, "last_update_posted_date": "2018-07-02", "last_synced_at": "2026-09-27T00:24:12.857Z", "location_count": 1, "location_summary": "Fort Worth, Texas", "locations": [ { "city": "Fort Worth", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02355028" }, { "nct_id": "NCT02302079", "title": "A Study to Evaluate ASP8232 in Reducing Central Retinal Thickness in Subjects With Diabetic Macular Edema (DME)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Diabetes Mellitus", "Diabetic Macular Edema" ], "interventions": [ { "name": "ASP8232", "type": "DRUG" }, { "name": "ranibizumab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Sham intravitreal (IVT) injection", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Astellas Pharma Europe B.V.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "18 Years to 85 Years" }, "enrollment_count": 96, "start_date": "2015-01-12", "completion_date": "2016-08-12", "has_results": false, "last_update_posted_date": "2024-10-31", "last_synced_at": "2026-09-27T00:24:12.857Z", "location_count": 21, "location_summary": "Phoenix, Arizona • Tucson, Arizona • Arcadia, California + 18 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Arcadia", "state": "California" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Palm Desert", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02302079" } ] }